Catalog
Long-acting GHRH analog

CJC-1295 (with/without DAC)

DAC variant binds albumin → multi-day half-life. Not FDA-approved; widely sold grey-market.

Research-only / unregulatedGrade D — Plausible, unprovenFDA Category 2 (2023) — barred from 503A compounding
Target
GHRHR

Mechanism of action

Modified GHRH(1–29) with drug-affinity complex (DAC) for albumin conjugation. Extends t½ from minutes to days, producing sustained (not pulsatile) GH elevation — physiologically abnormal.

Pharmacokinetics

SC. With DAC: t½ ~6–8 days (sustained GH bleed). Without DAC: short pulse-mimicking.

Clinical context

None FDA-approved. Off-label/grey-market 'anti-aging' use.

Safety

Contraindications
  • Active malignancy
  • Pituitary disease
  • Pregnancy
Adverse effects
  • Sustained IGF-1 elevation
  • Insulin resistance
  • Edema, arthralgia
  • Theoretical mitogenic risk

Relevant labs

IGF-1Hemoglobin A1c

Covered in modules

Module 05
Growth Hormone Secretagogues
CJC-1295, ipamorelin, sermorelin, tesamorelin, MK-677 — what's approved, what's compounded, what's hype.
Module 14
Safety, Regulation & Compounded Peptides
503A vs 503B vs research-only — what the FDA actually says.

Related compounds

GLP-1 receptor agonist
Semaglutide
GHRH analog
Tesamorelin
GHRH(1–29) analog
Sermorelin
Selective GH secretagogue (GHS-R agonist)
Ipamorelin

Generate prescriber-grade deep dive

Pull in expanded mechanism, PK/PD, dosing strategies for special populations, drug interactions, monitoring cadence, head-to-head differentials, prescriber pearls, and patient FAQs for CJC-1295 (with/without DAC).

Educational reference. Not medical advice. Always verify against current FDA labeling and local regulatory guidance before prescribing or counseling.